• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjects

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Circulating tumour DNA - looking beyond the blood

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Thumbnail
    Name:
    35915225.pdf
    Size:
    1.547Mb
    Format:
    PDF
    Description:
    Identified with Open Access button
    Download
    Authors
    Tivey, Ann
    Church, Matt
    Rothwell, Dominic G
    Dive, Caroline
    Cook, Natalie
    Affiliation
    Division of Cancer Sciences, The University of Manchester, Manchester, UK
    Issue Date
    2022
    
    Metadata
    Show full item record
    Abstract
    Over the past decade, various liquid biopsy techniques have emerged as viable alternatives to the analysis of traditional tissue biopsy samples. Such surrogate 'biopsies' offer numerous advantages, including the relative ease of obtaining serial samples and overcoming the issues of interpreting one or more small tissue samples that might not reflect the entire tumour burden. To date, the majority of research in the area of liquid biopsies has focused on blood-based biomarkers, predominantly using plasma-derived circulating tumour DNA (ctDNA). However, ctDNA can also be obtained from various non-blood sources and these might offer unique advantages over plasma ctDNA. In this Review, we discuss advances in the analysis of ctDNA from non-blood sources, focusing on urine, cerebrospinal fluid, and pleural or peritoneal fluid, but also consider other sources of ctDNA. We discuss how these alternative sources can have a distinct yet complementary role to that of blood ctDNA analysis and consider various technical aspects of non-blood ctDNA assay development. We also reflect on the settings in which non-blood ctDNA can offer distinct advantages over plasma ctDNA and explore some of the challenges associated with translating these alternative assays from academia into clinical use.
    Citation
    Tivey A, Church M, Rothwell D, Dive C, Cook N. Circulating tumour DNA - looking beyond the blood. Nature reviews Clinical oncology. 2022 Sep;19(9):600-12. PubMed PMID: 35915225. Pubmed Central PMCID: PMC9341152 Ingelheim, Biocartis, GRAIL and Merck, and has received research funding from Angle, Amgen, Astex Pharmaceuticals, AstraZeneca, Bayer, Bioven, Bristol Myers Squibb, Boehringer Ingelheim, Carrick Therapeutics, Celgene, Clearbridge Biomedics, Epigene Therapeutics, GlaxoSmithKline, Menarini, Merck AG, Neomed Therapeutics, Novartis, Roche, Taiho Oncology and Thermo Fisher Scientific. N.C. has received research funding from AstraZeneca, Avacta, Bayer, Boehringer, Eisai, Merck, Orion, Pfizer, RedX, Roche, Starpharma, Stemline Tarveda, Taiho Oncology and UCB. The other authors declare no competing interests. Epub 2022/08/02. eng.
    Journal
    Nature Reviews Clinical Oncology
    URI
    http://hdl.handle.net/10541/625545
    DOI
    10.1038/s41571-022-00660-y
    PubMed ID
    35915225
    Additional Links
    https://dx.doi.org/10.1038/s41571-022-00660-y
    Type
    Article
    Language
    en
    ae974a485f413a2113503eed53cd6c53
    10.1038/s41571-022-00660-y
    Scopus Count
    Collections
    All Christie Publications

    entitlement

    Related articles

    • The value of cell-free DNA for molecular pathology.
    • Authors: Stewart CM, Kothari PD, Mouliere F, Mair R, Somnay S, Benayed R, Zehir A, Weigelt B, Dawson SJ, Arcila ME, Berger MF, Tsui DW
    • Issue date: 2018 Apr
    • Analytical performance evaluation of a commercial next generation sequencing liquid biopsy platform using plasma ctDNA, reference standards, and synthetic serial dilution samples derived from normal plasma.
    • Authors: Verma S, Moore MW, Ringler R, Ghosal A, Horvath K, Naef T, Anvari S, Cotter PD, Gunn S
    • Issue date: 2020 Oct 1
    • [Liquid biopsy in colorectal cancer : An overview of ctDNA analysis in tumour diagnostics].
    • Authors: Haupts A, Roth W, Hartmann N
    • Issue date: 2019 Dec
    • Circulating tumor DNA: current challenges for clinical utility.
    • Authors: Dang DK, Park BH
    • Issue date: 2022 Jun 15
    • Extending Circulating Tumor DNA Analysis to Ultralow Abundance Mutations: Techniques and Challenges.
    • Authors: Rodda AE, Parker BJ, Spencer A, Corrie SR
    • Issue date: 2018 Mar 23
    DSpace software (copyright © 2002 - 2023)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.